



ALL MAIN INTERNATIONAL GUIDELINES RECOGNIZE ONIVYDE+5-FU/LV'S PROVEN EFFICACY¹⁻⁴

International guidelines consistently recommend ONIVYDE+5-FU/LV as the 2L treatment of choice after gem-based therapy¹⁻⁴

NCCN

NCCN guidelines recommend ONIVYDE+5-FU/LV in 2L post gemcitabine-based therapies and award ONIVYDE+5-FU/LV the only category 1 recommendation** for 2L treatment.¹

Guideline wording:

"Second-line therapy for locally advanced/ metastatic disease and therapy for recurrent disease: Good PS:

- if prior gemcitabine-based therapy: 5-FU + leucovorin + liposomal irinotecan (category 1 for metastatic disease)
- if prior fluoropyrimidine-based therapy: 5-FU + leucovorin + liposomal irinotecan (if no prior irinotecan)"¹

ESMO

ESMO guidelines recommend ONIVYDE+5-FU/LV in 2L post gemcitabine-based therapies for fit patients, before other options.^{2,3}

Guidelines wording:

"If the general status remains correct, considering the conflicting results on the use of oxaliplatin, MM398* when available in all countries may be the best option for second-line treatment of these patients"²

JPS

JPS guidelines recommend ONIVYDE+5-FU/LV as 2L therapy following gemcitabine-based therapy.⁴

Guideline wording:

"Use of a fluorouracil-containing regimen (including fluorouracil + calcium folinate + MM-398*) is recommended after a gemcitabine hydrochloride-containing regimen."⁴

2L, second line; 5-FU, 5-fluorouracil; ESMO, European Society for Medical Oncology; JPS, Japan Pancreas Society, LV, leucovorin; NCCN, National Comprehensive Cancer Network.
*MM398, ONIVYDE. **NCCN Category 1 Evidence and Consensus: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

1. Ducreux M et al. Ann Oncol. 2015;25(suppl 5):v56-v68. 2. eUpdate Cancer of the Pancreas Treatment Recommendations. Published June 20, 2017. ESMO Guidelines Committee. Available at: <https://www.esmo.org/Guidelines/Gastrointestinal-Cancers/Cancer-of-the-Pancreas/eUpdate-Treatment-Recommendations>. Last accessed July 2020. 3. Okusaka T et al. Pancreas. 2020;49:326-335. 4. NCCN Guidelines Version 1, 2020. Pancreatic Adenocarcinoma. Available at <https://www2.tri-kobe.org/nccn/guideline/pancreas/english/pancreatic.pdf>. Published November 26, 2019. Last accessed July 2020.

